רווח לפני ריבית, מסים ופחת: BioLineRx (BLRX)

EBITDA_Co dynamics demonstrate a real cash inflow from core operations, while 0.00 characterizes this valuation parameter. BioLineRx Ltd. (BLRX) is developing alliances with global pharma behemoths to advance its developments. BioLineRx Ltd. (BLRX) specializes in the hematology market, offering the drug Aphexda to clinics. The current development vector is focused on increasing hospital sales and international licensing following FDA approval.

This indicator measures net cash flow from operating activities before depreciation, allowing for an assessment of the business's actual ability to generate cash. An analysis of EBITDA in cash terms reveals the efficiency of operating expense management, which for BioLineRx Ltd. (BLRX) directly depends on retaining a staff of unique biochemists and protecting R&D competencies through a long-term incentive system for key specialists.